COVID-19 患者口腔表现:6 个月更新版
本文是对既往已发表的活系统评价的首次更新,旨在总结 COVID-19 患者口腔体征和症状的患病率证据。共纳入 183 项研究,报告了全球 64,876 例 COVID-19 患者的数据。味觉障碍总体患病率为 38%(95% CI = 22% 至 56%,I2 = 98%)。味觉障碍与 COVID-19 检测阳性相关(OR = 7.54,95% CI = 5.24 至 10.86,I2 = 93%,P < 0.00001),证据确定性高。口干症为本更新版新增特征,合并数据显示 COVID-19 患者中患病率为 43%(95% CI = 36% 至 50%,I2 = 71%)。口腔黏膜病变最常见的临床类型为阿弗他样,其次为疱疹样病变、念珠菌病、舌炎/舌乳头剥脱/地图舌、腮腺炎和口角炎。口腔病变更常见于舌、唇和腭部,临床表现多样,更可能代表合并感染。因此,对当前证据的再分析提示口干症、味觉功能障碍和口腔黏膜病变三联征是 COVID-19 患者的常见表现。然而,这些结果仍在讨论中,需要更多研究来确认其与口腔内直接 SARS-CoV-2 感染的关联。
要点
- 味觉障碍总体患病率 38%,与 COVID-19 检测阳性相关(OR = 7.54)。
- 口干症患病率 43%,为本次更新新增特征。
- 口腔黏膜病变以阿弗他样最常见,多见于舌、唇和腭。
核心结论
- 口干症、味觉功能障碍和口腔黏膜病变三联征可能是 COVID-19 患者的常见表现。
研究设计与样本
- 活系统评价的首次更新,共纳入 183 项研究,报告全球 64,876 例 COVID-19 患者数据。
主要发现
- 味觉障碍总体患病率为 38%(95% CI = 22% 至 56%,I2 = 98%)。
- 味觉障碍与 COVID-19 检测阳性相关(OR = 7.54,95% CI = 5.24 至 10.86,I2 = 93%,P < 0.00001),证据确定性高。
- 口干症合并患病率为 43%(95% CI = 36% 至 50%,I2 = 71%)。
- 口腔黏膜病变最常见为阿弗他样,其次为疱疹样病变、念珠菌病、舌炎/舌乳头剥脱/地图舌、腮腺炎和口角炎。
关键数值与推荐
- 味觉障碍与 COVID-19 检测阳性关联的 OR = 7.54(95% CI = 5.24 至 10.86,I2 = 93%,P < 0.00001),证据确定性高。
- 味觉障碍与 COVID-19 轻/中度严重程度关联的 OR = 1.63(95% CI = 1.33 至 1.99,I2 = 69%,P < 0.0001),证据确定性低。
- 味觉障碍与女性 COVID-19 患者关联的 OR = 1.77(95% CI = 1.26 至 2.48,I2 = 79%,P = 0.001),证据确定性低。
- 低味觉、味觉倒错和味觉丧失的合并患病率分别为 34%、33% 和 26%。
临床怎么用
- 口腔科医生应关注 COVID-19 患者的口干症、味觉功能障碍及口腔黏膜病变。
- 对舌、唇、腭部阿弗他样或疱疹样病变需考虑合并感染可能。
局限性
- 味觉障碍与轻/中度 COVID-19 及女性患者的关联证据确定性低。
- 口腔病变临床表现多样,更可能代表合并感染,与直接 SARS-CoV-2 感染的关联尚需更多研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This is the first update of the previously published living systematic review that summarized evidence on the prevalence of oral signs and symptoms in patients with COVID-19. Hitherto, 183 studies were included, reporting data from 64,876 patients with COVID-19 worldwide. The overall prevalence of taste disorders was 38% (95% CI = 22% to 56%, I2 = 98%). Hypogeusia, dysgeusia, and ageusia were also evaluated by a meta-analysis, and the pooled prevalence was 34% for hypogeusia, 33% for dysgeusia, and 26% for ageusia. Taste disorders were associated with a positive COVID-19 test (odds ratio [OR] = 7.54, 95% CI = 5.24 to 10.86, I2 = 93%, P < 0.00001), showing high certainty of evidence. However, the association between taste disorders and mild/moderate severity of COVID-19 (OR = 1.63, 95% CI = 1.33 to 1.99, I2 = 69%, P < 0.0001) and female patients with COVID-19 (OR = 1.77, 95% CI = 1.26 to 2.48, I2 = 79%, P = 0.001) presented low certainty of evidence. Xerostomia was a new feature of this update, and the pooled data demonstrated a prevalence of 43% (95% CI = 36% to 50%, I2 = 71%) in patients with COVID-19. Regarding oral mucosal lesions, the most common clinical pattern was aphthous like, followed by herpes-like lesions, candidiasis, glossitis/depapillation/geographic tongue, parotitis, and angular cheilitis. Oral lesions were more frequent in the tongue, lips, and palate, presenting miscellaneous clinical aspects that are more likely to represent coinfections. Therefore, the reanalysis of current evidence suggests the triad xerostomia, taste dysfunction, and oral mucosal lesions as common manifestations in patients with COVID-19. However, these outcomes are under discussion, and more studies will be necessary to confirm their association with direct SARS-CoV-2 infection in the oral cavity.
引用
- Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, et al. Oral Manifestations in Patients with COVID-19: A 6-Month Update. J Dent Res. 2021. PMID: 34324825. doi:10.1177/00220345211029637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。